Suppr超能文献

急性-on-慢性肝衰竭:当前的介入治疗选择与未来挑战。 (这里“on”可能有误,若为“Acute-on-Chronic Liver Failure”,更准确的表述可能是“慢加急性肝衰竭” )

Acute-On-Chronic Liver Failure: Current Interventional Treatment Options and Future Challenges.

作者信息

Kimmann Markus, Trebicka Jonel

机构信息

Department of Internal Medicine B, University of Münster, 48149 Münster, Germany.

European Foundation for the Study of Chronic liver Failure, EFCLIF, 08021 Barcelona, Spain.

出版信息

J Pers Med. 2023 Jun 26;13(7):1052. doi: 10.3390/jpm13071052.

Abstract

Acute-on-chronic liver failure (ACLF) is a frequent complication in patients with liver cirrhosis that has high short-term mortality. It is characterized by acute decompensation (AD) of liver cirrhosis, intra- and extrahepatic organ failure, and severe systemic inflammation (SI). In the recent past, several studies have investigated the management of this group of patients. Identification and treatment of precipitants of decompensation and ACLF play an important role, and management of the respective intra- and extrahepatic organ failures is essential. However, no specific treatment for ACLF has been established to date, and the only curative treatment option currently available for these patients is liver transplantation (LT). It has been shown that ACLF patients are at severe risk of waitlist mortality, and post-LT survival rates are high, making ACLF patients suitable candidates for LT. However, only a limited number of patients are eligible for LT due to related contraindications such as uncontrolled infections. In this case, bridging strategies (e.g., extracorporeal organ support systems) are required. Further therapeutic approaches have recently been developed and evaluated. Thus, this review focuses on current management and potential future treatment options.

摘要

慢加急性肝衰竭(ACLF)是肝硬化患者常见的并发症,短期死亡率很高。其特征为肝硬化急性失代偿(AD)、肝内外器官衰竭以及严重的全身炎症(SI)。最近,多项研究对这组患者的管理进行了调查。识别和治疗失代偿及ACLF的诱因起着重要作用,对相应肝内外器官衰竭的管理至关重要。然而,迄今为止尚未确立针对ACLF的特异性治疗方法,目前这些患者唯一的治愈性治疗选择是肝移植(LT)。研究表明,ACLF患者在等待名单上有很高的死亡风险,而肝移植后的生存率很高,这使得ACLF患者成为肝移植的合适候选者。然而,由于诸如感染未得到控制等相关禁忌证,只有少数患者符合肝移植条件。在这种情况下,需要采用桥接策略(如体外器官支持系统)。最近已经开发并评估了其他治疗方法。因此,本综述重点关注当前的管理方法以及未来可能的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8725/10381861/8a0df4ded18a/jpm-13-01052-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验